Sanofi Diabetes Franchise Could Get Boost From Retrophin’s Voucher
This article was originally published in The Pink Sheet Daily
Priority review ticket might be used on Type 2 diabetes combo LixiLan, expected to be filed later this year.
You may also be interested in...
US FDA approves Xultophy and Soliqua, both fixed-ratio combinations of a basal insulin and a GLP-1 agonist, on the same day even though Sanofi redeemed a priority review voucher that earned Soliqua an earlier user fee goal date.
Stakeholders push Congress to renew program, although 21st Century Cures route unlikely.
FDA request for more information on pen injector forces three-month review extension, offsetting advantage from priority review voucher redemption.